Biotech’s 2026 IPOs continued to outperform through August, with 18 of 21 companies trading above their IPO prices and 13 up more than 30% as of Sept. 1. The performance comes alongside a recovery in issuance, suggesting renewed appetite for public-market risk. The update matters for pipeline funding because stronger IPO windows typically reduce reliance on less liquid funding structures and can influence how companies plan timing for late-stage readouts, refinancing, and growth capital. Even with improvements, investors remain selective, and the market’s performance gradient is likely to shape which biotechs can access follow-on equity once clinical milestones start landing.